查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物溶離市場 - 全球和區域分析：按類型、最終用戶和區域 - 分析和預測（2024-2033）
市場調查報告書
商品編碼
1841467

藥物溶離市場 - 全球和區域分析：按類型、最終用戶和區域 - 分析和預測（2024-2033）

Pharmaceutical Dissolution Market - A Global and Regional Analysis: Focus on Type, End User, and Region - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 132 Pages | 商品交期: 1-5個工作天內

價格

藥物溶解是藥物（通常為片劑、膠囊或粉末形式）溶解在液體（通常模擬體液）中並釋放活性藥物成分（API）的過程。

這個過程對於了解藥物在體內如何發揮作用至關重要，因為它會影響藥物的生物有效性，也就是活性成分被吸收到血液中的速率和程度。溶離度測試在藥物開發和品質保證中起著至關重要的作用，確保製劑在患者使用時安全、有效且一致。它對於評估和改進口服劑型至關重要，並為藥物核准和合規提供必要的數據。

主要市場統計數據
預測期 2024-2033
2024年評估 6.494億美元
2033年的預測 13.112億美元
複合年成長率 8.12%

市場介紹

全球藥物溶解市場預計將大幅擴張，預計到 2035 年將達到 13.112 億美元。

藥物溶離市場在藥物開發、配方和品質保證中發揮關鍵作用。隨著監管要求的提高、技術創新的進步以及對改善患者預後的更加重視，預計未來幾年該市場將顯著成長和發展。藥物溶出是指藥物溶解在溶劑（通常是水或胃液）中並被吸收到血液中的過程。這是口服藥物藥物動力學中的關鍵步驟，因為它決定了活性藥物成分 (API) 被吸收的速率和程度。藥物的溶離速率影響其生物有效性、治療效果及整體臨床表現。在藥物開發中，溶離度測試是一種標準化方法，用於評估藥物從片劑、膠囊和混懸液等劑型中的釋放。 FDA 等監管機構要求進行此類測試，以確保藥物始終如一地按預期發揮作用並保持品質和安全標準。

在技​​術進步、監管要求和不斷發展的藥物開發策略的推動下，藥物溶出生態系統正在經歷快速創新。溶離測試技術不斷發展，融合了自動化、人工智慧和即時監控技術，在確保藥物在全球市場上取得成功方面發揮著更關鍵的作用。分析師越來越認知到溶出測試不僅是一項監管要求，也是藥物開發平臺中的關鍵組成部分，它有助於確保新藥的有效性和安全性，同時支持向更個性化和複雜的治療方法的持續轉變。

產品製造商－製藥公司是溶離度測試市場的核心，對測試服務和設備的需求不斷成長。製藥公司在藥物開發、生產和品質保證的各個階段的溶出度測試中都發揮著關鍵作用。例如，安捷倫科技公司已經擴展了其溶離度測試業務，並在藥物溶離度測試市場中處於領先地位。

服務供應商－CRO（委外研發機構）為製藥公司提供測試和研究服務，包括溶離度測試。對於那些缺乏內部專業知識或資源來執行此類專業工作的公司來說，CRO 尤其重要。

監管機構－美國FDA、EMA 和其他國家和國際監管機構參與制定藥物溶離度測試的監管標準和指南，並證明溶離度測試產品符合規定。

對產業的影響

製藥業對各領域的影響是廣泛且多方面的，影響公共衛生、經濟、就業和創新。

溶離度測試對於確保藥品的品質和一致性至關重要。溶離度測試有助於確認藥物活性成分 (API) 在特定條件下以正確的量和正確的速率釋放。這對於確保不同批次藥品的性能一致性至關重要。溶離度的差異可能導致藥效不一致，並影響病人安全。因此，溶離度測試是藥品生產品管的核心，確保產品符合嚴格的監管標準。

FDA、EMA 和 WHO 等監管機構已經建立了嚴格的溶離度測試通訊協定，以確保藥品在上市前符合安全和性能標準。製藥公司必須證明其產品能夠適當溶解，以便原料藥被人體吸收，而這必須透過溶出度測試來證明。這對於口服固體製劑（如片劑和膠囊）尤其重要，因為這些劑型的溶離度直接影響生物有效性。例如，在美國，FDA 關於即時釋和緩釋製劑溶離度測試的指南確保製藥公司遵守經過科學檢驗的方法來評估藥物在模擬生物環境中的釋放方式。

市場區隔

細分 1：按類型

  • 產品
    • 溶出系統
    • 溶離度附件
  • 服務

產品類型將繼續成為全球藥品溶解市場中按類型分類的領先細分市場，佔 2024 年市場佔有率的 63.43%，預計在 2024-2033 年預測期內的複合年成長率為 8.57%。

溶出系統及其配件在製藥市場佔據主導地位，主要原因在於它們在確保藥品品質、病人安全和法規遵循方面發揮關鍵作用。隨著技術、精度和永續性的不斷進步，這些產品能夠持續滿足藥物開發、生產和全球市場動態不斷變化的需求。隨著對品質保證、療效、成本效益和監管標準的持續關注，溶出系統在可預見的未來仍將是製藥業的基石。

細分 2：按最終用戶

  • 製藥和生物技術公司
  • CRO
  • 學術機構

從最終用戶來看，製藥和生技公司主導著藥物溶離市場，佔全球市場的48.57%。參與溶離度測試的製藥和生物技術公司專注於開發、生產和銷售能夠以適當速率溶解並確保活性藥物成分（API）可控且一致釋放的藥品。這種測試在新藥製劑開發過程中至關重要，並在藥品生產的品管中發揮關鍵作用。

細分3：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 其他
  • 拉丁美洲
  • 中東和非洲

北美在全球藥物溶離度測試市場中佔有最大的佔有率。這一成長得益於藥物配方的顯著進步、監管審查的加強以及溶出度測試在藥物研發 (R&D) 和生產過程中的日益普及。該地區競爭激烈，參與企業眾多，參與企業廣泛的產品和服務。知名市場參與企業包括安捷倫科技、SOTAX、Distek, Inc. 和 Catalent Inc.。

美國藥物溶離市場正經歷強勁成長，這主要得益於幾個關鍵因素，包括學名藥需求的不斷成長、監管標準日益嚴格、技術創新、製劑複雜性的不斷提升以及外包趨勢的日益成長。這些因素共同凸顯了溶離測試在確保藥物安全性、有效性和合規性方面發揮的關鍵作用，尤其是在企業應對不斷演變且日益複雜的法規環境之際。

由於藥品需求不斷成長以及監管標準日益嚴格，亞太地區藥物溶離度測試市場正在持續成長。儘管亞洲國家的藥物溶離度市場面臨著許多挑戰，包括監管複雜性、基礎設施缺口和勞動力短缺，但技術進步、學名藥的興起以及對品管的日益重視正在推動市場向前發展。隨著該地區製藥業的持續擴張，對準確且高效的溶離度測試的需求對於確保口服藥物的安全性和有效性至關重要。

藥物溶離市場的最新趨勢

  • 2024 年 5 月，Logan Instrument 推出了 EPVT-1200 系統，用於對 USP 裝置 1 和 2 進行性能驗證測試。這款創新的數位工具集以電子方式執行和記錄溶出驗證性能，消除了與手動記錄方法相關的不確定性。
  • 2024年8月，Logan Instruments Corp. 推出了最新創新產品－微球釋放測試系統。這款突破性產品旨在革新微球製劑測試和開發流程，滿足市場對先進藥物輸送解決方案日益成長的需求。

需求——促進因素、挑戰、機遇

市場促進因素

  • 製藥生產設施的擴張導致溶離度測試的需求增加

溶離度測試對於確保藥品的品質、安全性和有效性至關重要。隨著生產設施的擴張和產量的提高以滿足日益成長的全球需求，尤其是在新興市場，評估片劑和膠囊等口服固體製劑的溶出度特性的需求日益凸顯。此外，溶離度測試對於確保藥品符合監管標準並達到預期效果至關重要，這導致不斷擴張的生產設施對測試基礎設施的需求不斷增加。

領先的製藥公司正在開設新的設施，以支持其研發活動並擴大製造地。例如，賽默飛世爾科技公司於2024年4月在新加坡開設了一家新的無菌藥品生產設施，以支持亞太市場的藥品和疫苗的研發和生產。該符合cGMP標準的設施預計將為疫苗提供填充服務，從而增強公司現有的藥品開發和製造能力。

溶離度測試是製藥生產的重要組成部分，用於評估活性藥物成分 (API) 從片劑、膠囊和其他固態劑型中釋放到溶液中的速率。這個過程對於確定生物有效性和確保藥物的治療效果至關重要。

其他市場促進因素包括：

  • 個人化醫療在藥物溶離市場的整合

注意 - 所有上述因素都將在報告中詳細評估。

市場限制：

  • 進入藥物溶解市場的壁壘

資本需求：建立溶離度測試的生產和測試設施需要大量的資本投入。例如，對於進行藥物溶離度測試的中小型實驗室來說，初始資本投入（基本設定）可能在5萬至20萬美元之間，而整合分析工具的自動化高通量系統則需要超過50萬美元。如此高的資本需求對於藥物溶離度測試市場的中小型企業來說難以承受。此外，採購高品質原料和技術純熟勞工的成本也加重了財務負擔。

大型企業競爭激烈：藥物溶離市場競爭激烈，包括安捷倫科技公司、Distek公司、Sotax、康泰倫特和Charles River Laboratories等公司。該市場主要由擁有強大品牌知名度、廣泛基本客群以及全面產品和服務的老字型大小企業主導。新參與企業必須透過創新、更高品質和更高的成本效益來實現差異化，才能贏得市場佔有率。

注意 - 所有上述因素都將在報告中詳細評估。

市場機會：人工智慧和機器學習在藥物溶出的應用日益廣泛

人工智慧 (AI) 和機器學習 (ML) 正在透過提高包括溶離度測試在內的多個階段的效率、準確性和預測能力，徹底改變藥物開發。這些最尖端科技正擴大被應用於藥物研發 (R&D) 領域，以改善藥物配方、簡化測試流程並更準確地預測體內行為。

人工智慧可以評估配方與藥物成分（例如輔料和原料藥）之間的相互作用及其對溶出速率的影響。此功能有助於最佳化配方，以實現所需的溶出特性。機器學習模型可以確定成分和製程參數的最佳組合，以提高藥物釋放速率，從而提高藥物的療效和穩定性。

此外，人工智慧和機器學習正在透過增強流程最佳化、預測性維護和品管來改變製藥製造業。人工智慧演算法可以分析大型資料集並發現人類可能忽略的模式，從而提高效率並節省成本。

創造市場成長機會的其他因素包括：

  • 轉向先進的藥物溶離度測試

註 - 本報告對所有上述因素進行了詳細評估。

市場趨勢：

  • 溶離度測試設備的技術進步

溶離度測試設備的最新創新，包括自動化、高通量系統和即時監控，顯著提高了測試過程的效率、準確性和可靠性。這些進步使得更快、更準確地測量藥物釋放曲線成為可能，這對於產品開發和法規遵循都至關重要。自動化簡化了測試流程，降低了人為錯誤的風險並提高了通量，而高通量系統則可以同時測試多個樣品，從而加快了整體評估流程。此外，即時監控提供線上數據，有助於更深入地了解溶出過程，並根據需要進行即時調整。

這些技術發展正在改變溶離度測試的格局，使其更有效率、更具成本效益，最終使製藥公司和監管機構受益。因此，對尖端溶離度測試設備及相關技術的供應商的需求日益成長。提供先進溶離度測試設備、軟體解決方案和整合服務的公司將能夠充分利用這一趨勢，滿足製藥業對更快、更準確、更自動化的測試系統日益成長的需求。

注意 - 所有上述趨勢都將在報告中詳細評估。

產品/創新策略－本報告深入探討了藥物溶解領域的最新技術進步，使公司能夠推動創新並開發出滿足市場需求的尖端產品。

成長/行銷策略 - 透過提供全面的市場分析和識別關鍵的成長機會，公司能夠獲得制定有針對性的行銷策略和有效擴大其市場佔有率的知識。

競爭策略－該報告包括全面的競爭格局分析，以了解競爭對手在藥物溶解方面的優勢和劣勢，並制定有效的策略以在市場上獲得競爭優勢。

監管和合規策略 - 提供有關藥物溶解不斷發展的法律規範、核准和行業指南的最新資訊，使公司能夠保持合規並加速新藥物溶解的市場進入。

投資和業務擴大策略—透過分析市場趨勢、資金籌措模式和合作機會，我們幫助公司做出明智的投資決策並發現業務成長的潛在併購機會。

主要市場參與者和競爭對手的摘要

公司簡介是根據從主要專家收集的意見以及對公司覆蓋範圍、產品系列和市場滲透率的分析而選擇的。

全球藥物溶離市場正經歷強勁成長，這得益於美國FDA 和 EMA 等監管機構的推動，這些機構要求進行溶出測試以確保藥物品質和生物有效性，從而推動了行業需求。需要證明生物等效性的學名藥的興起進一步增加了對溶出測試的需求。自動化和即時測試等技術進步正在提高這些測試的速度、準確性和成本效益。此外，對新配方、複雜藥物輸送系統和生技藥品研發的日益關注也促進了市場成長。隨著個人化醫療的興起，專門的溶離測試方法變得越來越重要。將測試外包給 CRO 和 CDMO 的趨勢也在推動市場擴張。這些因素，加上對藥品安全和品質的關注，正在塑造全球藥物溶離市場。

該市場的一些知名公司包括：

  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Cytiva)
  • Sotax
  • Distek, Inc.
  • Agilent Technologies, Inc.
  • Waters Corporation

目錄

執行摘要

第1章調查方法

第2章：全球藥物溶離市場概述

第3章 市場產業展望

  • 市場概況與生態系統
  • 市場機會評估
  • 產品基準
  • 監管狀況/合規性
  • 膜採用分析（依類型）
  • 核准的溶離度測試中的膜型滲透
  • 市場動態概覽

4. 全球藥物溶離市場（按類型），百萬美元，2023-2033

  • 成長佔有率矩陣
  • 產品
  • 成長佔有率矩陣
    • 溶離度系統
    • 熔煉配件
  • 服務

5. 全球藥物溶離市場（以最終用戶分類），百萬美元，2023-2033 年

  • 成長佔有率矩陣
  • 製藥和生物技術公司
  • 合約研究組織（CRO）
  • 學術機構

6. 全球藥物溶離市場（按地區），百萬美元，2023-2033 年

  • 區域摘要
  • 成長佔有率矩陣
  • 北美洲
    • 區域概況
    • 驅動程式
    • 抑制因素
    • 美國
    • 加拿大
  • 歐洲
    • 區域概況
    • 驅動程式
    • 抑制因素
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 區域概況
    • 驅動程式
    • 抑制因素
    • 中國
    • 日本
    • 印度
    • 其他
  • 拉丁美洲
    • 區域概況
    • 驅動程式
    • 抑制因素
  • 中東和非洲
    • 區域概況
    • 驅動程式
    • 抑制因素

第7章 市場競爭狀況

  • 競爭基準化分析
  • 競爭格局
  • 公司簡介（主要製造商）
    • Agilent Technologies, Inc.
    • Merck KGaA
    • Thermo Fisher Scientific, Inc.
    • Danaher (Cytiva)
    • Catalent, Inc.
    • Distek, Inc.
    • Sotax
    • Almac Group
    • Teledyne Technologies Incorporated
  • 服務供應商
    • Charles River Laboratories International, Inc.
    • Eurofins Scientific
    • Intertek Group plc
    • Avivia BV
    • Boston Analytical
Product Code: BHL2545SA

This report can be delivered within 1 working day.

Introduction of Pharmaceutical Dissolution

Pharmaceutical dissolution is the process in which a drug, typically in the form of a tablet, capsule, or powder, dissolves in a liquid, usually a simulated bodily fluid, to release its active pharmaceutical ingredient (API). This process is vital for understanding how a drug functions within the body, as it influences the drug's bioavailability and how quickly and to what extent the active ingredient is absorbed into the bloodstream. Dissolution testing plays a critical role in pharmaceutical development and quality assurance, ensuring that the drug formulation is safe, effective, and consistent when used by patients. It is essential for evaluating and refining oral dosage forms and providing necessary data for drug approval and regulatory compliance.

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$649.4 Million
2033 Forecast$1,311.2 Million
CAGR8.12%

Market Introduction

The global pharmaceutical dissolution market is expected to witness significant expansion, projected to reach $1,311.2 million by 2035.

The pharmaceutical dissolution market plays a key role in drug development, formulation, and ensuring quality. As regulatory requirements increase, technological innovations advance, and there is a greater emphasis on enhancing patient outcomes, the market is set for significant growth and evolution in the coming years. Pharmaceutical dissolution refers to the process by which a drug dissolves in a solvent, typically water or gastric fluids, allowing it to be absorbed into the bloodstream. This is a crucial phase in the pharmacokinetics of oral medications as it determines the rate and extent to which the active pharmaceutical ingredient (API) becomes available for absorption. The dissolution rate of a drug affects its bioavailability, therapeutic effectiveness, and overall clinical performance. In pharmaceutical product development, dissolution testing is a standardized method used to assess the release of drugs from dosage forms like tablets, capsules, or suspensions. Regulatory agencies, such as the FDA, require this testing to ensure that drug products consistently perform as intended, maintaining quality and safety standards.

The pharmaceutical dissolution ecosystem is undergoing rapid innovation, driven by technological advancements, regulatory demands, and evolving drug development strategies. As dissolution testing continues to evolve with the integration of automation, AI, and real-time monitoring, it is poised to play an even more critical role in ensuring the success of pharmaceutical products in the global market. Analysts are increasingly recognizing dissolution testing not just as a regulatory requirement, but as a vital component of the drug development pipeline, helping to ensure both the efficacy and safety of new medications while supporting the ongoing shift toward more personalized and complex therapies.

Pharmaceutical dissolution ecosystem is multi-faceted in nature and involves various stakeholders that are involved in contributing towards market growth:

Product Manufacturers: At the heart of the dissolution testing market, pharmaceutical companies generate demand for testing services and equipment. They play a crucial role in carrying out dissolution testing throughout the stages of drug development, manufacturing, and quality assurance. For instance, Agilent Technologies, Inc. is at the forefront of driving the pharmaceutical dissolution market with expanding its dissolution business.

Service Providers: Contract Research Organizations (CROs) offer testing and research services to pharmaceutical companies, including dissolution testing. They are especially valuable for companies that lack the in-house expertise or resources to perform this specialized work.

Regulatory Authorities: Regulatory bodies such as the US FDA, EMA, and other national and international regulatory authority are involved in setting the regulatory standards and guidelines for pharmaceutical dissolution testing, certifying that dissolution testing products are under compliance.

Industrial Impact

The pharmaceutical industry's impact on various sectors is vast and multifaceted, affecting public health, economics, employment, and technological innovation.

Impact: Dissolution testing is crucial for ensuring the quality and consistency of pharmaceutical products. It helps verify that a drug's active pharmaceutical ingredient (API) is released at the correct rate and in the appropriate quantity, as expected under specific conditions. This is essential for ensuring that the drug performs consistently across different batches. Any variability in dissolution rates could lead to inconsistent drug efficacy, which could impact patient safety. Thus, dissolution testing forms a core part of quality control in pharmaceutical manufacturing, ensuring that products meet strict regulatory standards.

Regulatory bodies such as the FDA, EMA, and WHO have established strict dissolution testing protocols to ensure that drugs meet safety and performance criteria before being marketed. Pharmaceutical companies must demonstrate that their products dissolve appropriately for the API to be absorbed in the body, and this must be proven in dissolution testing. This is particularly important for oral solid dosage forms like tablets and capsules, where the dissolution profile directly affects bioavailability. For example, in the U.S., the FDA's guidance on dissolution testing for immediate-release and extended-release formulations ensures that pharmaceutical companies adhere to scientifically validated methods to assess how the drug is released in a simulated biological environment.

Market Segmentation:

Segmentation 1: By Type

  • Product
    • Dissolution System
    • Dissolution Accessories
  • Services

Product type remains the leading segment by type in the global pharmaceutical dissolution market, holding an 63.43% market share in 2024, with a projected CAGR of 8.57% during the forecast period 2024-2033.

The dominance of products i.e. dissolution systems and their accessories in the pharmaceutical market is primarily driven by their critical role in ensuring drug quality, patient safety, and regulatory compliance. With ongoing advancements in technology, precision, and sustainability, these products continue to meet the evolving needs of pharmaceutical development, manufacturing, and global market dynamics. The continuous focus on quality assurance, therapeutic efficacy, cost-effectiveness, and regulatory standards ensures that dissolution systems will remain a cornerstone of the pharmaceutical industry for the foreseeable future.

Segmentation 2: By End User

  • Pharmaceutical and Biotechnology Companies
  • CROs
  • Academic Institutions

Based on end user, pharmaceutical and biotechnology companies is dominating the pharmaceutical dissolution market, which accounted for 48.57% of the global market. Pharmaceutical and biotechnology companies engaged in dissolution testing focus on developing, producing, and marketing drug products that dissolve at the proper rate, ensuring the controlled and consistent release of active pharmaceutical ingredients (APIs). This testing is essential during the development of new drug formulations and plays a vital role in quality control within pharmaceutical manufacturing. is essential during the development of new drug formulations and plays a vital role in quality control within pharmaceutical manufacturing.

Segmentation 3: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Rest-of-Asia-Pacific
  • Latin America
  • MEA

North America dominates the global pharmaceutical dissolution market, holding the largest market share. This growth has been driven by significant advancements in drug formulations, increased regulatory scrutiny, and the growing adoption of dissolution testing in pharmaceutical research and development (R&D) as well as manufacturing processes. The region is highly competitive, with a mix of international and regional players offering a wide range of products and services. Prominent market players include Agilent Technologies, SOTAX, Distek, Inc., and Catalent Inc., among others.

The U.S. pharmaceutical dissolution market has been experiencing robust growth, fueled by several key factors, including the rising demand for generic drugs, stringent regulatory standards, technological innovations, the increasing complexity of drug formulations, and the growing trend of outsourcing. Together, these elements highlight the essential role that dissolution testing plays in ensuring pharmaceutical products' safety, efficacy, and regulatory compliance as companies address an evolving and increasingly complex regulatory environment

The pharmaceutical dissolution market in the Asia-Pacific region has been witnessing continuous growth owing to the rising demand for pharmaceutical products and stringent regulatory standards. Despite several challenges in the pharmaceutical dissolution market in Asian countries, such as regulatory complexity, infrastructure gaps, and a shortage of workforce, the market is advancing due to technological advancements, the rise of generics, and increased focus on quality control. As pharmaceutical manufacturing continues to expand in the region, the need for accurate and efficient dissolution testing will be critical in ensuring the safety and efficacy of oral medications.

Recent Developments in the Pharmaceutical Dissolution Market

  • In May 2024, Logan Instrument launched the "EPVT-1200 system" for USP apparatus 1 and 2 performance validation tests, focused on revolutionizing dissolution testers' validation process. This innovative digital toolset performs and records dissolution validation performance electronically, thereby eliminating the uncertainties associated with manual recording methods.
  • In August 2024, Logan Instruments Corp. unveiled its newest innovation, the Microsphere Release Testing System. This groundbreaking product is designed to transform the testing and development processes for microsphere dosage forms, meeting the increasing demand for advanced drug delivery solutions.

Demand -Drivers, Challenges, and Opportunities

Market Demand Drivers:

  • Expanding Pharmaceutical Manufacturing Facilities Leading to Increased Demand for Dissolution Testing

Dissolution testing is essential for ensuring the quality, safety, and efficacy of pharmaceutical products. As manufacturing facilities expand and increase production to meet the growing global demand, particularly in emerging markets, the need to evaluate the dissolution properties of oral solid dosage forms such as tablets and capsules becomes pronounced. Additionally, dissolution testing is crucial for ensuring that drugs comply with regulatory standards and perform as intended, leading to heightened demand for testing infrastructure within expanding manufacturing facilities.

Major juggernauts in the pharmaceutical industry are involved in opening new facilities to aid R&D activities and growing their manufacturing footprint. For instance, in April 2024, Thermo Fisher Scientific opened a new sterile drug production facility in Singapore to aid in the research, development, and manufacturing of medicines and vaccines for the Asia-Pacific market. This cGMP-compliant facility is expected to provide vaccine fill-finish services, enhancing companies' existing pharmaceutical development and production capabilities.

Dissolution testing is an essential component of pharmaceutical manufacturing, used to evaluate the rate at which active pharmaceutical ingredients (APIs) are released from tablets, capsules, or other solid dosage forms into a solution. This process is crucial for determining bioavailability and ensuring the therapeutic effectiveness of the medication.

Some of the other factors creating an drivers for market growth include:

  • Integration of Personalized Medicine in Pharmaceutical Dissolution Market

Note: All of the above factors will be evaluated in detail in the report.

Market Restraints:

  • Entry Barrier for New Entrants in Pharmaceutical Dissolution Market

Capital Requirement: Establishing manufacturing and testing facilities equipped for dissolution testing requires significant capital investment. For instance, for a small to mid-sized laboratory performing pharmaceutical dissolution testing, an approximate initial capital investment ranges from $50,000 to $200,000 for basic setups, and costs can increase to $500,000 or more for automated, high-throughput systems with integrated analysis tools. Such high capital requirements are unaffordable for small or mid-sized companies in the pharmaceutical dissolution market. Furthermore, the expenses involved in sourcing high-quality raw materials and developing a skilled workforce add to the financial burden.

Established Competition from Major Players: The pharmaceutical dissolution market is a competitive market such as Agilent Technologies, Inc., Distek, Inc., Sotax, Catalent, and Charles River Laboratories. The market is largely controlled by established companies with strong brand recognition, a broad customer base, and a comprehensive range of products and services. Challenging these dominant players is difficult, as new entrants must find ways to distinguish themselves through innovation, higher quality, or better cost-efficiency to capture market share.

Note: All of the above factors will be evaluated in detail in the report.

Market Opportunities: Rising Implementation of AI And ML for Pharmaceutical Dissolution

Artificial intelligence (AI) and machine learning (ML) are transforming pharmaceutical development by improving efficiency, accuracy, and predictive capabilities across multiple stages, including dissolution testing. These cutting-edge technologies are progressively being incorporated into pharmaceutical research and development (R&D) to enhance drug formulation, streamline testing procedures, and more accurately forecast in vivo behavior.

AI can assess the interactions between formulate and drug components (such as excipients and active pharmaceutical ingredients) and their impact on dissolution rates. This capability enables the optimization of drug formulations to achieve the desired dissolution properties. Machine learning models can determine the optimal combination of ingredients and processing parameters to enhance drug release rates, thereby improving both the drug's efficacy and stability.

Furthermore, AI and ML are transforming drug manufacturing by enhancing process optimization, predictive maintenance, and quality control. AI-powered algorithms can analyze large datasets and uncover patterns that might be overlooked by humans, leading to improved efficiency and cost reductions.

Some of the other factors creating an opportunity for market growth include:

  • Shift towards more sophisticated pharmaceutical dissolution testing

Note: All of the above factors will be evaluated in detail in the report.

Market Trends:

  • Technological Advancements in Dissolution Testing Apparatus

Recent innovations in dissolution testing equipment, including automation, high-throughput systems, and real-time monitoring, are significantly improving the efficiency, precision, and reliability of testing processes. These advancements enable faster and more accurate measurement of drug release profiles, which is essential for both product development and regulatory compliance. Automation streamlines the testing process, reducing the risk of human error and increasing throughput, while high-throughput systems lead to simultaneous testing of multiple samples, speeding up the overall evaluation process. Moreover, real-time monitoring provides on-line data, offering deeper insights into the dissolution process and allowing for immediate adjustments if required.

These technological developments are transforming the landscape of dissolution testing by making it more efficient and cost-effective, ultimately profiting both pharmaceutical companies and regulatory agencies. As a result, there is a growing demand for suppliers of cutting-edge dissolution testing equipment and related technologies. Companies that offer advanced dissolution apparatus, software solutions, and integration services stand to capitalize on this trend, catering to the increasing need for faster, more accurate, and automated testing systems in the pharmaceutical industry.

Note: All of the above trends will be evaluated in detail in the report.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in pharmaceutical dissolution, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in pharmaceutical dissolution and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to Pharmaceutical Dissolution, ensuring organizations stay compliant and accelerate market entry for new Pharmaceutical Dissolution

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2023. The market size has been estimated for FY2024 and projected for the period FY2023-FY2033.
  • The scope of this report has been carefully derived based on extensive interactions with experts and stakeholders across leading companies and research institutions worldwide. This report provides a comprehensive market of the Pharmaceutical Dissolution market.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available Pharmaceutical Dissolution products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in Pharmaceutical Dissolution, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

The global pharmaceutical dissolution market has been witnessing robust growth driven by the presence of regulatory bodies such as the U.S. FDA and EMA, which mandate dissolution testing to ensure the quality and bioavailability of pharmaceutical products, driving demand in the industry. The rise of generic drugs, which must demonstrate bioequivalence, further fuels the need for dissolution testing. Technological advancements, such as automation and real-time testing, enhance the speed, accuracy, and cost-effectiveness of these tests. Additionally, the increasing focus on R&D for new formulations, complex drug delivery systems, and biologics contributes to the market growth. As personalized medicine gains ground, specialized dissolution methods are becoming more crucial. The growing trend of outsourcing testing to CROs and CDMOs has also been supporting market expansion. These factors, along with a focus on drug safety and quality, are shaping the global pharmaceutical dissolution market.

Some prominent names established in this market are:

  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Cytiva)
  • Sotax
  • Distek, Inc.
  • Agilent Technologies, Inc.
  • Waters Corporation

Table of Contents

Executive Summary

1 Research Methodology

  • 1.1 Data Sources
    • 1.1.1 Primary Data Sources
    • 1.1.2 Secondary Data Sources
    • 1.1.3 Data Triangulation
  • 1.2 Market Estimation and Forecast

2 Global Pharmaceutical Dissolution Market: Overview

  • 2.1 Definitions
    • 2.1.1 Product Definition
  • 2.2 Inclusion and Exclusion Criteria
  • 2.3 Key Findings

3 Market Industry Outlook

  • 3.1 Market Overview and Ecosystem
  • 3.2 Market Opportunities Assessment
  • 3.3 Product Benchmarking
  • 3.4 Regulatory Landscape/Compliances
    • 3.4.1 U.S.
    • 3.4.2 European Union (EU)
    • 3.4.3 Japan
    • 3.4.4 China
  • 3.5 Membrane Adoption Analysis (by Type)
    • 3.5.1 Mixed Cellulose Ester (MCE)-based
    • 3.5.2 Polyvinylidene Fluoride (PVDF)-based
    • 3.5.3 Glass Fiber-based
    • 3.5.4 Nylon-based
    • 3.5.5 Polytetrafluoroethylene (PTFE)-based
    • 3.5.6 Others
  • 3.6 Membrane-Type Penetration in Approved Dissolution Tests
  • 3.7 Market Dynamics Overview
    • 3.7.1 Market Drivers
      • 3.7.1.1 Expanding Pharmaceutical Manufacturing Facilities Leading to Increased Demand for Dissolution Testing
      • 3.7.1.2 Integration of Personalized Medicine in Pharmaceutical Dissolution Market
      • 3.7.1.3 Role of Regulatory Standards in Shaping the Pharmaceutical Dissolution Market
    • 3.7.2 Market Restraints
      • 3.7.2.1 Presence of Alternative to Dissolution Testing
      • 3.7.2.2 Entry Barrier for New Entrants in Pharmaceutical Dissolution Market
      • 3.7.2.3 Various Challenges Faced by New Entrants
    • 3.7.3 Market Opportunities
      • 3.7.3.1 Rising Implementation of AI And ML for Pharmaceutical Dissolution
      • 3.7.3.2 Shift towards More Sophisticated Pharmaceutical Dissolution Testing
    • 3.7.4 Key Trends
      • 3.7.4.1 Technological Advancements in Dissolution Testing Apparatus
      • 3.7.4.2 Increasing Number of CROs and CDMOs Involved in Dissolution Testing
        • 3.7.4.2.1 Specialized Testing Services
        • 3.7.4.2.2 Quality Control of Drugs
        • 3.7.4.2.3 Adherence to Regulatory Standards during Dissolution Testing

4 Global Pharmaceutical Dissolution Market (by Type), $Million, 2023-2033

  • 4.1 Growth Share Matrix
  • 4.2 Product
  • 4.3 Growth Share Matrix
    • 4.3.1 Dissolution System
      • 4.3.1.1 Manual Dissolution System
      • 4.3.1.2 Automated Dissolution System
      • 4.3.1.3 Semi-Automated Dissolution System
    • 4.3.2 Dissolution Accessories
      • 4.3.2.1 Filters
        • 4.3.2.1.1 Syringe Filters
        • 4.3.2.1.2 Cannula Filters/Full Flow Filters
        • 4.3.2.1.3 Hollow Fiber Filters
      • 4.3.2.2 Dissolution Vessels
      • 4.3.2.3 Dissolution Baskets and Paddles
      • 4.3.2.4 Other Accessories
  • 4.4 Service

5 Global Pharmaceutical Dissolution Market (by End User), $Million, 2023-2033

  • 5.1 Growth Share Matrix
  • 5.2 Pharmaceutical and Biotechnology Companies
  • 5.3 Contact Research Organizations (CROs)
  • 5.4 Academic Institutions

6 Global Pharmaceutical Dissolution Market (By Region), $Million, 2023-2033

  • 6.1 Regional Summary
  • 6.2 Growth Share Matrix
  • 6.3 North America
    • 6.3.1 Regional Overview
    • 6.3.2 Driver
      • 6.3.2.1 Stringent Regulatory Framework
      • 6.3.2.2 Advancement in Dissolution Testing
      • 6.3.2.3 Increasing Demand for Biologics and Biosimilars
      • 6.3.2.4 Increasing Investment in R&D
    • 6.3.3 Restraints
      • 6.3.3.1 High Cost Associated with Dissolution Testing
      • 6.3.3.2 Evolving Regulatory Landscape
    • 6.3.4 U.S.
      • 6.3.4.1 Growing Trend of Outsourcing
      • 6.3.4.2 Expansion of the Pharmaceutical Manufacturing Sector
      • 6.3.4.3 High Cost Associated with Dissolution Testing
    • 6.3.5 Canada
      • 6.3.5.1 Stringent Regulatory Framework
      • 6.3.5.2 Increasing Demand for Generic Drugs
      • 6.3.5.3 Rising Government Initiatives
      • 6.3.5.4 Shortage of Skilled Workforce
      • 6.3.5.5 Evolving Regulatory Requirements
  • 6.4 Europe
    • 6.4.1 Regional Overview
    • 6.4.2 Drivers
      • 6.4.2.1 Stringent Regulatory Guidelines for Drug Approvals
      • 6.4.2.2 Growing Focus on Quality Assurance
      • 6.4.2.3 Technological Advancement in Dissolution Testing
    • 6.4.3 Restraints
      • 6.4.3.1 Discriminatory Power of Dissolution Methods
      • 6.4.3.2 Regulatory Complexity and Evolving Standards
    • 6.4.4 Germany
      • 6.4.4.1 Increasing Adoption of Generic Drugs
      • 6.4.4.2 Rising Interest in Biopharmaceuticals
      • 6.4.4.3 Growing Focus on Quality Assurance
      • 6.4.4.4 Shortage of Skilled Labor
      • 6.4.4.5 Rising Pressure on Cost Efficiency
    • 6.4.5 U.K.
      • 6.4.5.1 Shifting Trends toward Generic Drugs
      • 6.4.5.2 Innovation in Dissolution Testing Technologies
      • 6.4.5.3 Increasing Government Initiatives
      • 6.4.5.4 Challenges in Dissolution Testing
      • 6.4.5.5 Variability in Dissolution Tests Result
    • 6.4.6 France
      • 6.4.6.1 Increasing Demand for Generic Drugs
      • 6.4.6.2 High Emphasis on Quality Assurance
      • 6.4.6.3 Testing Complex Drug Formulations
      • 6.4.6.4 Technical Challenges in Biorelevant Dissolution Testing
    • 6.4.7 Italy
      • 6.4.7.1 Stringent Regulatory Guidelines for Drug Approvals
      • 6.4.7.2 Rising Focus on Complex Drug Formulation
      • 6.4.7.3 Long Approval Time
    • 6.4.8 Spain
      • 6.4.8.1 Rising Development in Biopharmaceutical Industry
      • 6.4.8.2 Focus on Regulatory Requirements
      • 6.4.8.3 Significant Vulnerabilities in the Pharmaceutical Dissolution Process
    • 6.4.9 Rest-of-Europe
      • 6.4.9.1 Government Funding and Support
      • 6.4.9.2 High Costs of Advanced Dissolution Testing Systems
      • 6.4.9.3 Technological Adoption in Emerging Markets
  • 6.5 Asia-Pacific
    • 6.5.1 Regional Overview
    • 6.5.2 Drivers
      • 6.5.2.1 Expanding Pharmaceutical Manufacturing in Asian Countries
      • 6.5.2.2 Increasing Biopharmaceutical and Outsourcing Testing Services
    • 6.5.3 Restraints
      • 6.5.3.1 Lack of Advanced Dissolution Testing Facilities
      • 6.5.3.2 Shortage of Skilled Professionals
    • 6.5.4 China
      • 6.5.4.1 Expanding Pharmaceutical Industry
      • 6.5.4.2 Rising Demand for Generic Drugs
      • 6.5.4.3 High Competition from Low-Cost Markets
      • 6.5.4.4 Shortage of Skilled Workforce
    • 6.5.5 Japan
      • 6.5.5.1 Technological Advancements in Dissolution Testing
      • 6.5.5.2 Rising Focus on Drug Development
      • 6.5.5.3 Regulatory Standardization and Complexity
    • 6.5.6 India
      • 6.5.6.1 Growth in the Generic Drug Development
      • 6.5.6.2 Ease of Access to Outsourcing Dissolution Services
      • 6.5.6.3 Shortage of Skilled Workforce for Dissolution Procedure
    • 6.5.7 Rest-of-Asia-Pacific
      • 6.5.7.1 Growth in Pharmaceutical Manufacturing Facilities
      • 6.5.7.2 Counterfeit Drugs and Quality Control Concerns
  • 6.6 Latin America
    • 6.6.1 Regional Overview
    • 6.6.2 Driver
      • 6.6.2.1 Availability of State-of-Art Pharmaceutical Dissolution Suppliers
      • 6.6.2.2 Outsourcing of Analytical Services by Pharmaceutical Companies
      • 6.6.2.3 Rising Pharmaceutical R&D in Latin America
    • 6.6.3 Restraints
      • 6.6.3.1 Limited Access to Dissolution Testing and Technologies
      • 6.6.3.2 Lack of in-house Dissolution Testing
  • 6.7 Middle East and Africa (MEA)
    • 6.7.1 Regional Overview
    • 6.7.2 Driver
      • 6.7.2.1 Expansion of Pharmaceutical Manufacturing Facilities
      • 6.7.2.2 Rising Focus on Drug Development Formulation
    • 6.7.3 Restraints
      • 6.7.3.1 Lack of Advanced Infrastructure
      • 6.7.3.2 Shortage of Skilled Workforce for Dissolution Testing

7 Markets - Competitive Landscape

  • 7.1 Competitive Benchmarking
  • 7.2 Competitive Landscape
    • 7.2.1 Corporate Strategies, January 2021-September 2024
    • 7.2.2 Business Expansions
    • 7.2.3 Mergers and Acquisitions
    • 7.2.4 Funding Activities
    • 7.2.5 Regulatory Approval and Product Launch January 2021-September 2024
    • 7.2.6 Key Developments Analysis
    • 7.2.7 Company Share Analysis, 2023
      • 7.2.7.1 Dissolution System
      • 7.2.7.2 Dissolution Accessories
  • 7.3 Company Profiles (Major Manufacturers)
    • 7.3.1 Agilent Technologies, Inc.
      • 7.3.1.1 Overview
      • 7.3.1.2 Top Products
        • 7.3.1.2.1 Dissolution System
        • 7.3.1.2.2 Dissolution Accessories
      • 7.3.1.3 Top Competitors
      • 7.3.1.4 Target Customers/End Users
      • 7.3.1.5 Analyst View
    • 7.3.2 Merck KGaA
      • 7.3.2.1 Overview
      • 7.3.2.2 Top Products
        • 7.3.2.2.1 Dissolution Accessories
      • 7.3.2.3 Top Competitors
      • 7.3.2.4 Target Customers/End Users
      • 7.3.2.5 Analyst View
    • 7.3.3 Thermo Fisher Scientific, Inc.
      • 7.3.3.1 Overview
      • 7.3.3.2 Top Products
        • 7.3.3.2.1 Dissolution System
      • 7.3.3.3 Top Competitors
      • 7.3.3.4 Target Customers/End Users
      • 7.3.3.5 Analyst View
    • 7.3.4 Danaher (Cytiva)
      • 7.3.4.1 Overview
      • 7.3.4.2 Top Products
        • 7.3.4.2.1 Dissolution Accessories
      • 7.3.4.3 Top Competitors
      • 7.3.4.4 Target Customers/End Users
      • 7.3.4.5 Analyst View
    • 7.3.5 Catalent, Inc.
      • 7.3.5.1 Overview
      • 7.3.5.2 Top Products
        • 7.3.5.2.1 Dissolution System
      • 7.3.5.3 Top Competitors
      • 7.3.5.4 Target Customers/End Users
      • 7.3.5.5 Analyst View
    • 7.3.6 Distek, Inc.
      • 7.3.6.1 Overview
      • 7.3.6.2 Top Products
        • 7.3.6.2.1 Dissolution System
      • 7.3.6.3 Top Competitors
      • 7.3.6.4 Target Customers/End Users
      • 7.3.6.5 Analyst View
    • 7.3.7 Sotax
      • 7.3.7.1 Overview
      • 7.3.7.2 Top Products
        • 7.3.7.2.1 Dissolution System
        • 7.3.7.2.2 Pharma Services
      • 7.3.7.3 Top Competitors
      • 7.3.7.4 Target Customers/End Users
      • 7.3.7.5 Analyst View
    • 7.3.8 Almac Group
      • 7.3.8.1 Overview
      • 7.3.8.2 Top Products
        • 7.3.8.2.1 Dissolution Testing Equipment
      • 7.3.8.3 Top Competitors
      • 7.3.8.4 Target Customers/End Users
      • 7.3.8.5 Analyst View
    • 7.3.9 Teledyne Technologies Incorporated
      • 7.3.9.1 Overview
      • 7.3.9.2 Top Products
        • 7.3.9.2.1 Dissolution Accessories
      • 7.3.9.3 Top Competitors
      • 7.3.9.4 Target Customers/End Users
      • 7.3.9.5 Analyst View
  • 7.4 Service Providers
    • 7.4.1 Charles River Laboratories International, Inc.
      • 7.4.1.1 Overview
      • 7.4.1.2 Services Offered
      • 7.4.1.3 Top Competitors
      • 7.4.1.4 Target Customers/End Users
      • 7.4.1.5 Analyst View
    • 7.4.2 Eurofins Scientific
      • 7.4.2.1 Overview
      • 7.4.2.2 Services Offered
      • 7.4.2.3 Top Competitors
      • 7.4.2.4 Target Customers/End Users
      • 7.4.2.5 Analyst View
    • 7.4.3 Intertek Group plc
      • 7.4.3.1 Overview
      • 7.4.3.2 Services Offered
      • 7.4.3.3 Top Competitors
      • 7.4.3.4 Target Customers/End Users
      • 7.4.3.5 Analyst View
    • 7.4.4 Avivia BV
      • 7.4.4.1 Overview
      • 7.4.4.2 Services Offered
      • 7.4.4.3 Top Competitors
      • 7.4.4.4 Target Customers/End Users
      • 7.4.4.5 Analyst View
    • 7.4.5 Boston Analytical
      • 7.4.5.1 Overview
      • 7.4.5.2 Services Offered
      • 7.4.5.3 Top Competitors
      • 7.4.5.4 Target Customers/End Users
      • 7.4.5.5 Analyst View

List of Figures

  • Figure 1: Market Snapshot in 2023, 2026, 2033
  • Figure 2: Global Pharmaceutical Dissolution Market (by Region), $Billion, 2023, 2026, and 2033
  • Figure 3: Global Pharmaceutical Dissolution Market (by Type), $Billion, 2023, 2026, and 2033
  • Figure 4: Global Pharmaceutical Dissolution Market (by End User), $Billion, 2023, 2026, and 2033
  • Figure 5: Global Pharmaceutical Dissolution Market (by Product), $Billion, 2023, 2026, and 2033
  • Figure 6: Global Pharmaceutical Dissolution Market (by Dissolution Accessories), $Billion, 2023, 2026, and 2033
  • Figure 7: Global Pharmaceutical Dissolution Market (by Filters), $Billion, 2023, 2026, and 2033
  • Figure 8: Data Triangulation
  • Figure 9: Top-Down and Bottom-Up Approach
  • Figure 10: Assumptions and Limitations
  • Figure 11: Inclusion and Exclusion of the Study
  • Figure 12: Global Pharmaceutical Dissolution Market Size, $ Million, 2023-2033
  • Figure 13: Various Parameters Considered during Testing
  • Figure 14: Manufacturing Facilities in Various Regions
  • Figure 15: Examples of Companies Expanding their Pharmaceutical Manufacturing Facilities
  • Figure 16: Global Personalized Medicine Market
  • Figure 17: Various Aspects of Personalised Medicine in Dissolution Testing
  • Figure 18: Key Regulatory Standards Changing the Dynamics of Pharmaceutical Dissolution Market
  • Figure 19: Global Pharmaceutical Dissolution Market, Growth-Share Matrix (by End User), 2023-2033
  • Figure 20: Products Used for Dissolution Testing
  • Figure 21: Various Accessories used for Dissolution Testing
  • Figure 22: Key Services in Dissolution Testing
  • Figure 23: Global Pharmaceutical Dissolution Market, Growth-Share Matrix (by End User), 2023-2033
  • Figure 24: Global Pharmaceutical Dissolution Market, Growth-Share Matrix (by Region), 2023-2033
  • Figure 25: U.S. Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 26: Canada Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 27: Germany Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 28: U.K. Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 29: France Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 30: Italy Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 31: Spain Pharmaceutical Dissolution Market, $Million, 2032-2023
  • Figure 32: Rest-of-Europe Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 33: China Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 34: Japan Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 35: India Pharmaceutical Market Turnover (In USD)
  • Figure 36: India Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 37: Rest-of-Asia-Pacific Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 38: Latin America Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 39: Middle East and Africa Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Figure 40: Corporate Strategies, January 2021-September 2024
  • Figure 41: Key Areas of Development in Pharmaceutical Dissolution Market
  • Figure 42: Company Share Analysis, 2023
  • Figure 43: Company Share Analysis, 2023

List of Tables

  • Table 1: Market Snapshot Scenario
  • Table 2: Drug Release Conditions and Acceptance Criteria
  • Table 3: Impact Analysis of Market Navigating Factors, 2023-2033
  • Table 4: Some Examples of Alternative Techniques
  • Table 5: List of Big Pharmaceutical Companies Embracing AI and ML for Dissolution Process
  • Table 6: Recent Technological Advancements by Companies
  • Table 7: Global Pharmaceutical Dissolution Market (by Product and Service), $Million, 2023-2033
  • Table 8: Global Pharmaceutical Dissolution Market (by Product), $Million, 2023-2033
  • Table 9: Companies Offering Manual Dissolution System
  • Table 10: Companies Offering Automated Dissolution System
  • Table 11: Companies Offering Semi-Automated Dissolution System
  • Table 12: Examples of Companies Offering Syringe Filters
  • Table 13: Examples of Companies Offering Cannula Filters
  • Table 14: Companies Offering Dissolution Vessels
  • Table 15: Examples of Companies Offering Baskets and Paddles
  • Table 16: Examples of Companies Offering Dissolution Shafts
  • Table 17: Global Pharmaceutical Dissolution Market (by End User), $Million, 2023-2033
  • Table 18: Examples of Pharmaceutical and Companies Offering Dissolution Procedure
  • Table 19: Global Pharmaceutical Dissolution Market (by Region), $Million, 2023-2033
  • Table 20: North America Pharmaceutical Dissolution Market (by Country), $Million, 2023-2033
  • Table 21: Europe Pharmaceutical Dissolution Market (by Country), $Million, 2023-2033
  • Table 22: Asia-Pacific Pharmaceutical Dissolution Market, $Million, 2023-2033
  • Table 23: Partnerships, Alliances, and Business Expansions (by Company), January 2021-September 2024
  • Table 24: Mergers and Acquisitions (by Company), January 2021-September 2024
  • Table 25: Funding and Investment Activities (by Company), January 2021-September 2024